We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Refractive Surgery and Optive Compatibility Study

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00469157
First Posted: May 4, 2007
Last Update Posted: April 17, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Innovative Medical
May 2, 2007
May 4, 2007
April 17, 2008
May 2007
April 2008   (Final data collection date for primary outcome measure)
Assess compatibility [ Time Frame: 8 months ]
Not Provided
Complete list of historical versions of study NCT00469157 on ClinicalTrials.gov Archive Site
comfort [ Time Frame: 8 months ]
Not Provided
Not Provided
Not Provided
 
Refractive Surgery and Optive Compatibility Study
Refractive Surgery and Optive Compatibility Study
To assess the compatibility of Optive with refractive surgery (PRK and LASIK) post-operatively.
Not Provided
Interventional
Phase 4
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Dry Eye Syndromes
Drug: Optive
Optive 30ml- (in the eye) Instill one in each eye twice daily starting one week after surgery
1.
Intervention: Drug: Optive
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
92
April 2008
April 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Men and women 18 and over
  • Patients undergoing refractive surgery

Exclusion Criteria:

  • Concurrent ocular conditions or pathology that could affect patient's ability to complete study
  • Concurrent use of topical medications other than study medications
  • Use of systemic medications with ocular drying sequelae:

    • Antihistamines
    • Decongestants
    • Antispasmotics
    • Antidepressants
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00469157
5303
Not Provided
Not Provided
Not Provided
Loren Rude, OD, TLC
Innovative Medical
Not Provided
Principal Investigator: Loren Rude, OD TLC
Innovative Medical
April 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP